Total Payments
$345,058
2024 Payments
$121,874
Companies
25
Transactions
320
Medicare Patients
993
Medicare Billing
$136,601
Payment Breakdown by Category
Other$225,327 (65.3%)
Consulting$91,623 (26.6%)
Travel$16,484 (4.8%)
Food & Beverage$9,007 (2.6%)
Research$2,455 (0.7%)
Education$161.98 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $130,112 | 56 | 37.7% |
| Compensation for serving as faculty or as a speaker for a medical education program | $93,415 | 27 | 27.1% |
| Consulting Fee | $91,623 | 54 | 26.6% |
| Travel and Lodging | $16,484 | 56 | 4.8% |
| Food and Beverage | $9,007 | 111 | 2.6% |
| Unspecified | $2,455 | 9 | 0.7% |
| Honoraria | $1,800 | 1 | 0.5% |
| Education | $161.98 | 6 | 0.0% |
Payments by Type
General
$342,603
311 transactions
Research
$2,455
9 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eisai Inc. | $281,336 | 211 | $0 (2024) |
| Astellas Pharma US Inc | $18,536 | 13 | $0 (2024) |
| Seagen Inc. | $15,514 | 17 | $0 (2023) |
| PFIZER INC. | $6,339 | 6 | $0 (2024) |
| EMD Serono, Inc. | $4,925 | 3 | $0 (2024) |
| Aveo Pharmaceuticals, Inc. | $3,384 | 16 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $3,091 | 4 | $0 (2024) |
| Gilead Sciences, Inc. | $2,570 | 1 | $0 (2022) |
| Exelixis Inc. | $2,247 | 5 | $0 (2024) |
| Dendreon Pharmaceuticals LLC | $2,125 | 3 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $121,874 | 77 | Eisai Inc. ($99,832) |
| 2023 | $126,578 | 104 | Eisai Inc. ($105,929) |
| 2022 | $82,348 | 89 | EISAI INC. ($74,801) |
| 2021 | $8,928 | 11 | E.R. Squibb & Sons, L.L.C. ($3,048) |
| 2020 | $1,939 | 14 | Merck Sharp & Dohme Corporation ($1,448) |
| 2019 | $2,434 | 15 | Dendreon Pharmaceuticals LLC ($2,125) |
| 2018 | $387.68 | 4 | Genentech USA, Inc. ($267.41) |
| 2017 | $569.11 | 6 | Amgen Inc. ($326.02) |
All Payment Transactions
320 individual payment records from CMS Open Payments — Page 1 of 13
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/23/2024 | EMD Serono, Inc. | — | Consulting Fee | Cash or cash equivalent | $2,375.00 | General |
| 12/05/2024 | Exelixis Inc. | CABOMETYX (Drug) | Honoraria | Cash or cash equivalent | $1,800.00 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 11/21/2024 | Aveo Pharmaceuticals, Inc. | FOTIVDA (Drug) | Food and Beverage | In-kind items and services | $100.54 | General |
| Category: Oncology | ||||||
| 11/20/2024 | Eisai Inc. | — | Food and Beverage | In-kind items and services | $70.51 | General |
| 11/08/2024 | PFIZER INC. | PADCEV (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,125.00 | General |
| Category: Oncology | ||||||
| 11/07/2024 | Eisai Inc. | Lenvima (Drug) | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | $1,570.00 | General |
| Category: Oncology | ||||||
| 09/19/2024 | Eisai Inc. | Lenvima (Drug) | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | $1,570.00 | General |
| Category: Oncology | ||||||
| 08/03/2024 | Astellas Pharma US Inc | Padcev (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,795.00 | General |
| Category: Oncology | ||||||
| 08/03/2024 | Astellas Pharma US Inc | Padcev (Drug) | Travel and Lodging | Cash or cash equivalent | $841.43 | General |
| Category: Oncology | ||||||
| 08/03/2024 | Astellas Pharma US Inc | Padcev (Drug) | Travel and Lodging | Cash or cash equivalent | $815.39 | General |
| Category: Oncology | ||||||
| 08/03/2024 | Astellas Pharma US Inc | Padcev (Drug) | Travel and Lodging | Cash or cash equivalent | $317.05 | General |
| Category: Oncology | ||||||
| 08/03/2024 | Astellas Pharma US Inc | Padcev (Drug) | Food and Beverage | In-kind items and services | $3.51 | General |
| Category: Oncology | ||||||
| 07/30/2024 | Eisai Inc. | Lenvima (Drug) | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | $6,280.00 | General |
| Category: Oncology | ||||||
| 07/30/2024 | Eisai Inc. | Lenvima (Drug) | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | $1,962.50 | General |
| Category: Oncology | ||||||
| 07/30/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | Cash or cash equivalent | $85.30 | General |
| Category: Oncology | ||||||
| 07/30/2024 | Eisai Inc. | Lenvima (Drug) | Travel and Lodging | Cash or cash equivalent | $62.00 | General |
| Category: Oncology | ||||||
| 07/30/2024 | Eisai Inc. | Lenvima (Drug) | Travel and Lodging | Cash or cash equivalent | $36.00 | General |
| Category: Oncology | ||||||
| 07/29/2024 | Eisai Inc. | Lenvima (Drug) | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | $6,280.00 | General |
| Category: Oncology | ||||||
| 07/29/2024 | Eisai Inc. | Lenvima (Drug) | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | $2,355.00 | General |
| Category: Oncology | ||||||
| 07/29/2024 | Eisai Inc. | Lenvima (Drug) | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | $1,962.50 | General |
| Category: Oncology | ||||||
| 07/29/2024 | Eisai Inc. | Lenvima (Drug) | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | $1,962.50 | General |
| Category: Oncology | ||||||
| 07/29/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | Cash or cash equivalent | $98.18 | General |
| Category: Oncology | ||||||
| 07/29/2024 | Eisai Inc. | Lenvima (Drug) | Travel and Lodging | Cash or cash equivalent | $44.52 | General |
| Category: Oncology | ||||||
| 07/29/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | Cash or cash equivalent | $17.00 | General |
| Category: Oncology | ||||||
| 07/22/2024 | Eisai Inc. | Lenvima (Drug) | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | $6,280.00 | General |
| Category: Oncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | Aveo Pharmaceuticals, Inc. | $2,455 | 9 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 292 | 474 | $141,941 | $39,237 |
| 2022 | 6 | 335 | 555 | $165,100 | $46,957 |
| 2021 | 3 | 170 | 270 | $83,431 | $25,603 |
| 2020 | 8 | 196 | 327 | $94,698 | $24,804 |
Total Patients
993
Total Services
1,626
Medicare Billing
$136,601
Procedure Codes
28
All Medicare Procedures & Services
28 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 103 | 177 | $43,542 | $12,086 | 27.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 68 | 138 | $33,948 | $9,352 | 27.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 42 | 42 | $21,378 | $5,673 | 26.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 25 | 53 | $18,497 | $5,246 | 28.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 40 | 50 | $17,450 | $4,990 | 28.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 14 | 14 | $7,126 | $1,891 | 26.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 102 | 169 | $41,138 | $11,543 | 28.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 79 | 134 | $32,964 | $9,937 | 30.1% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 19 | 90 | $26,730 | $7,191 | 26.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 34 | 49 | $17,101 | $5,066 | 29.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 33 | 33 | $16,797 | $4,165 | 24.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 19 | 30 | $10,470 | $3,080 | 29.4% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 17 | 17 | $8,415 | $2,642 | 31.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 17 | 17 | $8,653 | $2,433 | 28.1% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2022 | 15 | 16 | $2,832 | $898.40 | 31.7% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 45 | 80 | $19,680 | $5,915 | 30.1% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 36 | 73 | $17,958 | $5,527 | 30.8% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 36 | 48 | $16,752 | $5,238 | 31.3% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 22 | 38 | $13,262 | $4,475 | 33.7% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 31 | 31 | $15,779 | $4,448 | 28.2% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 37 | 90 | $22,140 | $5,262 | 23.8% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 25 | 61 | $18,117 | $4,826 | 26.6% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 25 | 27 | $13,365 | $4,230 | 31.7% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 26 | 26 | $13,234 | $3,119 | 23.6% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 22 | 51 | $10,710 | $2,827 | 26.4% |
About Dr. Arnab Basu, MD
Dr. Arnab Basu, MD is a Hematology & Oncology healthcare provider based in Jacksonville, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/12/2012. The National Provider Identifier (NPI) number assigned to this provider is 1669734083.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Arnab Basu, MD has received a total of $345,058 in payments from pharmaceutical and medical device companies, with $121,874 received in 2024. These payments were reported across 320 transactions from 25 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($130,112).
As a Medicare-enrolled provider, Basu has provided services to 993 Medicare beneficiaries, totaling 1,626 services with total Medicare billing of $136,601. Data is available for 4 years (2020–2023), covering 28 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Hematology & Oncology
- Location Jacksonville, FL
- Active Since 06/12/2012
- Last Updated 07/07/2025
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1669734083
Products in Payments
- Lenvima (Drug) $281,226
- PADCEV (Biological) $20,068
- Padcev (Drug) $18,036
- FOTIVDA (Drug) $3,249
- OPDIVO (Biological) $3,064
- Bavencio (Drug) $2,550
- CABOMETYX (Drug) $2,247
- PROVENGE (Drug) $2,125
- PADCEV (Drug) $2,000
- MK-6482 (Drug) $1,448
- XTANDI (Drug) $502.96
- IMFINZI (Biological) $400.00
- TECENTRIQ (Biological) $267.41
- XGEVA (Biological) $240.19
- FIRMAGON (Drug) $104.18
- JAKAFI (Drug) $98.71
- Aranesp (Biological) $85.83
- Nplate (Biological) $56.69
- BENDEKA (Drug) $48.42
- VENCLEXTA (Biological) $23.92
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Jacksonville
Edith Perez, Md, MD
Hematology & Oncology — Payments: $282,574
Hematology & Oncology $282,574
Saranya Chumsri, Md, MD
Hematology & Oncology — Payments: $259,129
Hematology & Oncology $259,129
Sikander Ailawadhi, Md, MD
Hematology & Oncology — Payments: $244,554
Hematology & Oncology $244,554
James Foran, Md, MD
Hematology & Oncology — Payments: $157,939
Hematology & Oncology $157,939
Dr. Gregory Pennock, Md, MD
Hematology & Oncology — Payments: $133,778
Hematology & Oncology $133,778
Richard Joseph, Md, MD
Hematology & Oncology — Payments: $128,971
Hematology & Oncology $128,971